Laurie A. Milner, M.D.

Laurie A. Milner, M.D.

Contact Information

University of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 704
Rochester, NY 14642

Office: (585) 276-5651
Fax: (585) 276-0350
Administrative: (585) 273-3258

Professional Bio

Dr. Milner is a board certified Pediatric Hematologist/Oncologist with particular expertise in blood and marrow transplantation. During her Fellowship and Junior Faculty years at the Fred Hutchinson Cancer Research Center in Seattle, Dr. Milner gained experience with transplantion for both pediatric and adult patients. In addition to serving as an attending physician for Pediatric Hematology, Oncology and BMT patients, she also attends on the Adult BMT unit at URMC/SMH and has recently been appointed Medical Director of the Inpatient/Outpatient (IPOP) Unit for the BMT Program.



Dr. Milner was previously the Principal Investigator for a basic laboratory research program focusing on the role of Notch signaling in hematopoietic and vascular differentiation of embryonic stem cells. Her current efforts are directed toward the translation of stem cell laboratory research to clinical transplantation studies and protocols. This interest is facilitated by her role as Medical Director of the Stem Cell Processing Laboratory at URMC/SMH.

Research Bio

Dr. Milner's research interests are:



1) Stem Cells
2) Hematopoiesis
3) Transplantation
4) The role of Notch signaling during hematopoietic differentiation of embryonic stem cells.

Research in her laboratory is guided by two fundamental questions: what are the molecular mechanisms responsible for the generation of diverse cell types from pluripotent stem cells, and how do aberrations in normal developmental pathways contribute to pediatric malignancies?

As a model system, they are using embryonic stem (ES) cells to evaluate the role of Notch signaling in hematopoietic cell fate decisions. Signaling through the Notch pathway is critical for appropriate cell fate specification during a variety of developmental processes. The unique capacity of Notch to function both as a cell-surface receptor and transcriptional regulator provides a mechanism by which cell-cell interactions can directly influence gene expression in neighboring cells. This direct communication between cells has two important effects: promoting the self-renewal of uncommitted progenitors and directing equipotent progenitors in the same microenvironmental context to adopt distinct cell fates.

Mammalian hematopoiesis is a unique developmental process in which stem cells continue to generate vast numbers of diverse cell types throughout adult life. As in other systems, Notch appears to influence cell fate decisions at multiple steps during hematopoiesis, having effects that are determined by the presence of specific inductive signals and the precise maturational state of the cell. Defining the role of Notch signaling during hematopoiesis is complicated both by the number of Notch receptors and DSL ligands expressed by hematopoietic and stromal cells, and by the interactions of Notch with other signaling pathways within the intricate hematopoietic regulatory network.

Using a gene targeting strategy to conditionally express the different Notch receptors and DSL ligands at defined stages of in vitro ES cell differentiation and in vivo hematopoiesis, they hope to delineate the effects of Notch signaling on lineage specification and self-renewal of progenitors at various stages of hematopoietic commitment. Their previous studies, as well as those of other investigators, suggest that, in the appropriate context, Notch signaling delays differentiation and promotes expansion of hematopoietic stem/progenitor cells.

Therefore, one of their immediate goals is to use Notch signaling to generate large numbers of hematopoietic stem cells from ES cells; these ES cell-dervived HSCs could provide a versatile alternative stem cell source for transplantation. Given the pervasive role of Notch during development, it's not surprising that aberrations in Notch signaling have been associated with a number of malignancies, including leukemias and lymphomas.

Thus, Dr. Milner hopes that their work will also provide insights as to how alterations in Notch signaling may contribute to pediatric malignancies, many of which represent normal developmental processes gone awry.

Awards & Honors (National)

Molecular Medicine in Cancer Research Scholar Award | James S. McDonnell Foundation | Seattle, WA (FHCRC) 1995 - 1997

Awards & Honors (Local)

Child Health Research Center New Investigator Award | University of Washington | Seattle, WA 1994 - 1995

Recent Journal Articles

Showing the 5 most recent journal articles. 27 available »

2013
Hashmi, S*; Oliva, JL*; Liesveld, JL; Milner, LA; Phillips, GL II; Becker, MW. "The hematopoietic cell transplantation specific comorbidity Index and survival after extracorporeal photopheresis, pentostatin, and reduced dose total body irradiation conditioning prior to allogeneic stem cell transplantation." Leukemia Research. 2013; 37(9): 1052-1056.
2013
Liesveld,JL; Phillips,GL II; Becker, M; Constine, LS ; Friedberg, J; Andolina, JR; Milner, LA; DeBolt, J; Smudzin, T; Hyrien, O; Erickson-Miller, CL; Johnson, BM; Dawson, KL; Chen, Y. "A Phase 1 Trial of Eltrombopag in Patients Undergoing Stem Cell Transplantation after Total Body Irradiation". Biology of Blood and Marrow Transplant. 2013; 19: 1745-1752.
2012
Ban-Hoefen; M*; Kelly, JL*; Bernstein, SH; Liesveld, JL; Constine, LS; Becker, MW; Milner, LA; Phillips, GL; Friedberg, JW. "High-dose therapy and autologous stem cell transplant (HD-ASCT) for transformed non-Hodgkin lymphoma (NHL) in the rituximab era". Leukemia and Lymphoma. 2012; 53(5): 830-835.
2012
Reid R; Bennett JM; Becker M; Chen Y; Milner L; Phillips G; Liesveld, J. "Use of eltrombopag, a thrombopoietin receptor agonist, in post-transplantation thrombocytopenia". American Journal of Hematology. 2012; 87(7): 743-745.
2011
Phillips, GL; Bernstein,S; Liesveld, JL; Abboud,CN; Becker, MW; Constine, LS; Ifthikharuddin, JJ; Loughner, JE; Milner, LA; Vesole DH; Friedberg, JW. "A phase I dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection." Biology of Blood and Marrow Transplantation. 2011; 17: 1033-1042.

Specialties

Pediatrics - American Board of Pediatrics
Pediatric Hematology-Oncology - American Board of Pediatrics

Education

MD | University of Texas - Southwestern Medical School1986
BS | Microbiology | University of Montana1978

Post-Doctoral Training & Residency

Fellowship in Pediatric Hematology/Oncology at Fred Hutchinson Cancer Research Center07/01/1990 - 06/30/1994
Fellowship in Research Fellow at Virginia Mason Medical Center07/01/1989 - 06/30/1990
Residency in Pediatrics at University of Washington07/01/1987 - 07/01/1989
Internship in Pediatrics at University of Washington06/25/1986 - 06/30/1987